Michigan State University, Spectrum Health and Lansing-based company Niowave have teamed up to develop a new strategy to fight cancer
A potential new weapon against cancer is entering the first phase of clinical trials thanks to a collaboration between Spectrum Health, the Lansing-based company Niowave and Michigan State University.
Digital communication is a way to bridge the racial disparity gap in cervical cancer information and follow up.
An estimated 14,480 new cases of invasive cervical cancer will be diagnosed in the United States this year, according to the American Cancer Society. Cases that could be prevented or cured with better education from screening to treatment based on improved provider-patient communication, says a Michigan State University researcher.
The issue is particularly acute for Black women, said Sabrina Ford, an associate professor in the Department of Obstetrics, Gynecology and Reproductive Biology within MSU’s College of Human Medicine. Ford’s research was published online Feb. 1 in the journal Gynecologic Oncology.
Henry Ford Health System and Michigan State University, two of the state’s leading education, research and health care institutions, are partnering to make Michigan a national leader in providing access to exceptional health care for all residents, scientific discovery and education for providers, patients and families.
In a landmark partnership that will last for at least 30 years, both institutions are committed to aligning efforts across key departments and programs to achieve critical health care and educational goals, while addressing social issues that impact health outcomes for patients in Michigan and beyond.
In the United States, 1 in 8 women will develop breast cancer, according to the American Cancer Society, and many of them are unwittingly making a serious choice every time they apply sunscreen: should they expose their skin to the sun or their mammary cells to a potentially cancer-causing chemical?
Research led by Michigan State University researchers in the College of Natural Science is the first of its kind to show that the common sunscreen ingredient benzophenone-3, also known as oxybenzone or BP-3, can play a role in the development of mammary gland tumors.